Taiyen Biotech Future Growth

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Taiyen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1737 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	3,409	300	109	455	N/A
9/30/2023	3,486	389	20	332	N/A
6/30/2023	3,541	399	616	828	N/A
3/31/2023	3,555	408	527	774	N/A
12/31/2022	3,614	427	334	581	N/A
9/30/2022	3,969	419	734	1,014	N/A
6/30/2022	4,116	357	-142	289	N/A
3/31/2022	4,229	418	79	425	N/A
12/31/2021	4,096	393	209	600	N/A
9/30/2021	3,758	431	-204	200	N/A
6/30/2021	3,391	427	152	422	N/A
3/31/2021	3,196	402	101	280	N/A
12/31/2020	3,130	365	71	339	N/A
9/30/2020	3,008	318	160	409	N/A
6/30/2020	3,027	308	13	333	N/A
3/31/2020	2,955	316	61	399	N/A
12/31/2019	2,907	346	44	329	N/A
9/30/2019	2,905	335	45	351	N/A
6/30/2019	2,878	337	215	447	N/A
3/31/2019	2,996	460	245	483	N/A
12/31/2018	3,001	453	151	450	N/A
9/30/2018	2,933	452	53	390	N/A
6/30/2018	2,925	475	37	459	N/A
3/31/2018	2,783	375	0	395	N/A
12/31/2017	2,757	354	238	530	N/A
9/30/2017	2,749	357	N/A	556	N/A
6/30/2017	2,747	347	N/A	472	N/A
3/31/2017	2,782	349	N/A	581	N/A
12/31/2016	2,755	352	N/A	568	N/A
9/30/2016	2,762	317	N/A	581	N/A
6/30/2016	2,752	338	N/A	568	N/A
3/31/2016	2,751	289	N/A	471	N/A
12/31/2015	2,761	269	N/A	384	N/A
9/30/2015	2,722	289	N/A	402	N/A
6/30/2015	2,669	223	N/A	348	N/A
3/31/2015	2,608	186	N/A	370	N/A
12/31/2014	2,576	214	N/A	371	N/A
9/30/2014	2,566	210	N/A	348	N/A
6/30/2014	2,507	181	N/A	287	N/A
3/31/2014	2,475	161	N/A	207	N/A
12/31/2013	2,409	126	N/A	203	N/A
9/30/2013	2,379	105	N/A	182	N/A
6/30/2013	2,320	90	N/A	138	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1737's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 1737's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1737's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1737's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1737's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1737's Return on Equity is forecast to be high in 3 years time

Taiyen Biotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Full year 2023 earnings released: EPS: NT$1.50 (vs NT$2.13 in FY 2022)

Taiyen Biotech Co., Ltd., Annual General Meeting, Jun 21, 2024

Upcoming dividend of NT$1.50 per share at 4.4% yield

Second quarter 2023 earnings released: EPS: NT$0.19 (vs NT$0.23 in 2Q 2022)

Taiyen Biotech Co., Ltd. Approves Cash Dividend, Payable on September 19, 2023

High number of new directors

Taiyen Biotech Co., Ltd. Announces Director Changes

New major risk - Revenue and earnings growth

Taiyen Greenenergy Co., LTD. Announces Resignation of Yi-Hui Tsai as Director of Financial& Accounting, Effective June 20, 2023

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.97 in FY 2021)

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.97 in FY 2021)

Taiyen Biotech Co., Ltd. Change of the Spokesperson

Third quarter 2022 earnings released: EPS: NT$0.81 (vs NT$0.50 in 3Q 2021)

Taiyen Biotech Co., Ltd. Replaces Wang, Ching-Sen with Chuang, Mei-Yu as Chief Internal Auditor, with Effect from November 16, 2022

Upcoming dividend of NT$1.50 per share

Second quarter 2022 earnings released: EPS: NT$0.23 (vs NT$0.53 in 2Q 2021)

Taiyen Biotech Co., Ltd. Announces Cash Dividend, Payable on September 20, 2022

Taiyen Biotech Co., Ltd. Announces Executive Changes

First quarter 2022 earnings released: EPS: NT$0.64 (vs NT$0.51 in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.50 (vs NT$0.48 in 3Q 2020)

Upcoming dividend of NT$1.35 per share

Second quarter 2021 earnings released: EPS NT$0.53 (vs NT$0.41 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.33 in 1Q 2020)

Taiyen Biotech (TPE:1737) Has A Pretty Healthy Balance Sheet

Taiyen Biotech's (TPE:1737) Returns On Capital Are Heading Higher

Full year 2020 earnings released: EPS NT$1.83 (vs NT$1.73 in FY 2019)

A Look At The Intrinsic Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

Is Taiyen Biotech Co., Ltd. (TPE:1737) Popular Amongst Institutions?

Taiyen Biotech Co., Ltd. (TPE:1737) Stock's On A Decline: Are Poor Fundamentals The Cause?

New 90-day low: NT$31.85

Taiyen Biotech Co., Ltd. (TPE:1737) Investors Should Think About This Before Buying It For Its Dividend

New 90-day low: NT$32.05

Taiyen Biotech (TPE:1737) Seems To Use Debt Quite Sensibly

Returns On Capital - An Important Metric For Taiyen Biotech (TPE:1737)

A Look At The Fair Value Of Taiyen Biotech Co., Ltd. (TPE:1737)

How Much Of Taiyen Biotech Co., Ltd. (TPE:1737) Do Institutions Own?

Shareholders Of Taiyen Biotech (TPE:1737) Must Be Happy With Their 53% Return

Third quarter 2020 earnings released: EPS NT$0.48

New 90-day high: NT$32.70

New 90-day low - NT$30.60

First half earnings released

First half earnings released

New 90-day high - NT$31.95

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies